Nature's Sunshine Products (NATR) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nature's Sunshine Products (NATR) has outperformed Cartesian Therapeutics (RNAC) over the past year, losing 16.2% versus a loss of 33.3%. Over five years, NATR leads with a -18.2% price change compared with -94.7% for RNAC. Nature's Sunshine Products is the larger company by market cap ($222.6 million vs $211.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NATR | RNAC |
|---|---|---|
| Share price | $12.65 | $6.99 |
| Market cap | $222.58M | $211.48M |
| 1-day change | +0.64% | +2.49% |
| YTD return | -41.75% | -5.41% |
| 1-year return | -16.20% | -33.33% |
| 5-year return | -18.22% | -94.68% |
| P/E ratio (TTM) | 12.52 | — |
| Forward P/E | 10.28 | — |
| EPS (TTM) | $1.01 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.14 | $11.00 |
| 52-week low | $12.31 | $5.60 |
| Distance from 52-week high | -55.05% | -36.45% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +141.11% | +381.69% |
| Average volume | 160.23K | 133.50K |
| Shares outstanding | 17.60M | 30.26M |
| Employees | 806 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NATR has outperformed RNAC by 17.1 percentage points over the past year.
About Nature's Sunshine Products
NATR stock →Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune products to support and strengthen the human immune system.
Health Care · Biotechnology: Pharmaceutical Preparations · 806 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
NATR vs RNAC FAQ
Which is bigger, Nature's Sunshine Products or Cartesian Therapeutics?
Nature's Sunshine Products (NATR) is larger, with a market capitalization of $222.58M compared with $211.48M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, NATR or RNAC?
NATR returned -16.20% over the past 12 months, compared with -33.33% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are Nature's Sunshine Products and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.